The Cure Starts Now follows an extensive grant approval process to ensure your dollars make the biggest impact to homerun cancer research. Take comfort in knowing that The Cure Starts Now only funds: research that follows our mission, research that is non-duplicative, and research that is financially sound.


The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




SONALASENSE – $198,436

Amount
$198,436.00
Date
November 2022

A Phase 1/2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2 in Patients With DIPG

UPMC Childrens Hospital of Pittsburgh – $100,000

Amount
$100,000.00
Date
November 2022

The Role of QPRT and NAD Pathways in DIPG Treatment Resistance (Continued)

The Hospital For Sick Children (SickKids) – $100,000

Amount
$100,000.00
Date
November 2022

Synthetic lethality screening with methionine restriction for treatment of DIPG

University of Texas MD Anderson Cancer Center – $100,000

Amount
$100,000.00
Date
November 2022

Viroimmunotherapy for pediatric brain tumors

Hunter Medical Research Institute – $200,000

Amount
$200,000.00
Date
November 2022

DMG COMBATT 2.0: Diffuse Midline Glioma COMbined Anti-Tumor Targeting 2.0

The Institute of Cancer Research – $501,183

Amount
$501,183.00
Date
November 2022

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG)

Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

SIOPe DIPG/DMG Registry – $779,018

Amount
$779,018.00
Date
March 2022

Renewal of the European DIPG/DMG Registry

Funding of PBTCF 2022 - $25,000

Amount
$25,000.00
Date
January 2022

Massachusetts General Hospital – $50,000

Amount
$50,000.00
Date
November 2021

Targeted Protein Degradation for DIPG Therapy

CONNECT2007 - $345,794

Amount
$345,794.00
Date
September 2021

Phase I/II Study of Lutathera in Pediatric and Young Adult Patients with Recurrent and/or Progressive High-Grade Central Nervous System (CNS) Tumors and Meningiomas which Express Somatostatin Type 2A Receptors and Demonstrate Uptake on DOTATATE

CONNECT2109A - $705,764

Amount
$705,764.00
Date
September 2021

CONNECT2109A: A molecularly-guided phase II study of ribociclib and everolimus in children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG)

CONNECT Consortium - $278,619

Amount
$278,619.00
Date
September 2021

Immuno-Modulation to Treat Poor-Prognosis Pediatric Brain Tumors

Institute of Cancer Research – $113,747

Amount
$113,747.00
Date
September 2021

Co-Culture Disruptor Screens to Target Cell-Cell Interactions in DMG

Institute of Cancer Research – $498,716

Amount
$498,716.00
Date
September 2021

Translating Mechanism to Patient Benefit for ACVR1-Mutant Diffuse Intrinsic Pontine Glioma (DIPG) - An International Connect Consortium Preclinical / Clinical